BioSpace News Archive

MIB Agents, a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for its community of patients, caregivers, doctors, and researchers, announced that since its inception in 2016, it has awarded over $1.9 million to scientists across the country through its OutSmarting Osteosarcoma grant program.

Tonix Pharmaceuticals Holding Corp., a fully-integrated biopharmaceutical company, announced it has entered into a placement agency agreement for the purchase and sale of 3,753,558 shares of its common stock at an offering price of $1.065 per share.

Revive Therapeutics Ltd. announced today an update on the Type C meeting written responses received by the Company from the U.S. Food & Drug Administration (“FDA”) for the evaluation of a proposed clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for Long COVID (the “Study”).

The Colorectal Cancer Resource & Action Network (CCRAN) is proud to announce their second annual Pan-Tumor Biomarkers Conference, scheduled to take place virtually on June 20-21, 2024, from 9:30 AM to 5:00 PM ET.

Zumutor Biologics Inc. “Zumutor”, a Boston-based clinical stage Oncology Company developing first-in-class monoclonal antibody molecules targeting innate immunological pathways, today announced that the first patient was dosed in its Phase 1 clinical trial, with ZM008.

Springbok Analytics (www.springbokanalytics.com), a life sciences muscle analytics company, announced today its participation in a Phase 1 Clinical Trial to evaluate safe dosage for clenbuterol as a treatment for Facioscapulohumeral muscular dystrophy (FSHD).

Positron Corporation (“Positron” or the “Company”) (OTC: POSC) is pleased to announce it has entered an agreement to acquire the FDA 510(k) for the NeuSight PET-CT from its cooperative partner Neusoft Medical Systems’ subsidiary, Shenyang Intelligent Neuclear Medical Technology Co.

Melbourne, Australia, 12 June 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce...

Toronto, Ontario--(Newsfile Corp. - June 12, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3D0A) (“Telo” or the “Company”), is pleased to announce that results of the development, validation and implementation of its machine learning and Artificial Intelligence (AI) modules, used in its TeloView myeloma diagnostic tests, were presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting that took place in Chicago, USA between May 30-June 4, 2024.

Mutations are changes in the molecular “letters” that make up the DNA code, the blueprint for all living cells. Some of these changes can have little effect, but others can lead to diseases, including cancer.